Tyme Technologies, Inc. (NASDAQ: TYME) stock was down -27.20% to $93.96 in the premarket session today. It seems the stock is giving back part of the gains it achieved last night. The stock was up 93.96% to $3.53 at the previous close. On a year-to-date basis, the stock is up 189.34%. The stock index has gained 163.43% over the past month and 306.73% over the last three months. It has had excellent performance over the past six months, as it achieved 171.54%, and in the previous 52 weeks, it has made over 145.14%.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Latest Development
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Tyme Technologies, Inc. (NASDAQ: TYME) has just announced that it has entered into a final arrangement with a range of healthcare-focused retail and other institutional buyers to sell a total of 40,000,000 shares of its common stock at a purchase price of $2.50 per share in a listed direct offering priced on the market under the Nasdaq rules. The bid is supposed to near or close. It is anticipated that this offering will close in early February 2021, subject to the satisfaction of customary closing conditions.
Read More
The offering is being handled by H.C. Wainwright & Co., exclusive placement agent.
Before deduction of placement agent’s fees and other offering expenses, the offering’s gross proceeds are expected to be $100 million. For the offering’s net profits, TYME intends to use as working capital, capital expenditures, and general and administrative expenses and further develop the company’s clinical and preclinical assets.
The company may also use a portion of the net proceeds to acquire or invest in complementary businesses, products, and technologies. However, as of this communication date, the company does not have any plans, commitments, or agreements regarding any acquisitions.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Finally,
Tyme Technologies, Inc., an emerging biotechnology company, develops cancer therapeutics with low toxicity profiles and broad application across tumor types. Researchers predict we live in an excellent time for Biotech. Therefore, investors are expected to make a fortune if their products are approved.
